{"nctId":"NCT01363713","briefTitle":"A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis","startDateStruct":null,"conditions":["Allergic Conjunctivitis"],"count":130,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: DE-114 ophthalmic solution"]}],"interventions":[{"name":"DE-114 ophthalmic solution","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Provided signed, written informed consent.\n* Has a positive result from a Type I allergy test.\n* If a subject is a female of childbearing potential, she must utilize reliable contraceptive throughout the study, and must have a negative urine pregnancy test prior to enrollment into this study.\n\nExclusion Criteria:\n\n* Females who are pregnant, nursing or planning a pregnancy, or females of childbearing potential who are not using a reliable method of contraception.\n* Presence of any abnormality or significant illness that could be expected to interfere with the study.","sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Ocular Itching Score by Visit","description":"Change from baseline in the average of Ocular itching score over the past 3 days. Ocular itching was assessed by the subject and graded on a 5 points scale of 0-4 (0=no itching, 4=incapacitating itch).\n\nThe main purpose of this study is not to confirm but to evaluate safety of long term use of this drug, so primary variable was not defined.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.7","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"0.1"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Palpebral Hyperemia Score by Visit","description":"Change from baseline of palpebral hyperemia score. Palpebral hyperemia was assessed by the investigator and graded on a 4 points scale of 0-3 (0=none and 3= extremely severe).\n\nThe main purpose of this study is not to confirm but to evaluate safety of long term use of this drug, so primary variable was not defined.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"0.1"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Bulbar Conjunctiva Hyperemia Score by Visit","description":"Change from baseline of bulbar conjunctiva hyperemia score. Bulbar conjunctiva hyperemia was assessed by the investigator and graded on a 4 points scale of 0-3 (0=none and 3= extremely severe).\n\nThe main purpose of this study is not to confirm but to evaluate safety of long term use of this drug, so primary variable was not defined.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"0.1"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":130},"commonTop":["Nasopharyngitis"]}}}